Showing 3531-3540 of 5646 results for "".
- Pangaea Data Secures Investment from Topcon Healthcare to Scale AI Platformhttps://modernod.com/news/pangaea-data-secures-investment-from-topcon-healthcare-to-scale-ai-platform/2482821/Pangaea Data announced an investment from Topcon Healthcare to accelerate the application of Pangaea’s AI platform, which aims to address care gaps in eye health and systemic disease. Financial terms of the deal were not disclosed.
- Nicox to Receive Milestone Payments from Kowa as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japanhttps://modernod.com/news/nicox-to-receive-milestone-payments-from-kowa-as-ncx-470-prepares-to-enter-phase-3-clinical-trials-in-japan/2482819/Nicox SA announced that its exclusive Japanese partner for NCX 470, Kowa, has received Clinical Trial Notification (equivalent of a US Investigational New Drug, IND) approval to initiate phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Ja
- Eylea 8 mg Approved in China for Wet AMDhttps://modernod.com/news/eylea-8-mg-approved-in-china-for-wet-amd/2482817/The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial a
- FDA Approves Genentech’s Susvimo for Diabetic Retinopathyhttps://modernod.com/news/fda-approves-genentechs-susvimo-for-diabetic-retinopathy/2482815/Genentech has received FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). The approval makes Susvimo the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with one refill ever
- Bausch + Lomb Launches Lumify Preservative Free Redness Reliever Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-the-united-states/2482814/Bausch + Lomb announced the US launch of Lumify Preservative Free redness reliever eye drops, which the company describes as the first and only preservative-free over-the-counter (OTC) eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to m
- Grifols Receives FDA Clearance to Initiate Phase 2 Trial of Immunoglobulin Drops for Dry Eye Diseasehttps://modernod.com/news/grifols-receives-fda-clearance-of-ind-application-for-phase-2-trial-of-immunoglobulin-drops-for-dry-eye-disease/2482812/Grifols, a producer of plasma-derived medicines, announced that the FDA has cleared the company’s investigational new drug (IND) application to initiate a phase 2 trial evaluating its immunoglobulin (IG) drops–GRF312 ophthalmic solution–fo
- Atsena Therapeutics Announces Positive Clinical Data for Gene Therapy to Treat X-linked Retinoschisis (XLRS)https://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-for-gene-therapy-to-treat-x-linked-retinoschisis-xlrs/2482808/Atsena Therapeutics announced interim data from Part A of its phase 1/2 LIGHTHOUSE clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study demonstrated a favorable safety profile and compelling signs of efficacy in adul
- NIH Study: Experimental Drug May Help Treat Condition May Help Treat Diabetic Retinopathyhttps://modernod.com/news/nih-study-experimental-drug-may-help-treat-condition-may-help-treat-diabetic-retinopathy/2482805/A new National Institutes of Health (NIH)-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nu
- New World Medical Introduces Next-Generation Streamline Surgical Systemhttps://modernod.com/news/new-world-medical-introduces-next-generation-streamline-surgical-system-1/2482803/New World Medical has announced the launch of its enhanced Streamline Surgical System, which features a transparent tip designed to provide surgeons with improved visualization of key anatomical structures throughout the procedure. This latest advancement builds upon the original Streamline
- Bausch + Lomb Launches Zenlens CHROMA HOA in the UShttps://modernod.com/news/bausch-lomb-launches-zenlens-chroma-hoa-in-the-us/2482802/Bausch + Lomb announced the US launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos an